Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INGN Stock Forecast 2025-2026
$6.75
Current Price
$177.19M
Market Cap
Buy 1
Hold 1
Sell 1
Wall St Analyst Ratings
Distance to INGN Price Targets
+33.3%
To High Target of $9.00
+33.3%
To Median Target of $9.00
+33.3%
To Low Target of $9.00
INGN Price Momentum
+10.8%
1 Week Change
-5.6%
1 Month Change
-23.4%
1 Year Change
-26.4%
Year-to-Date Change
-49.4%
From 52W High of $13.33
+18.4%
From 52W Low of $5.70
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Inogen (INGN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on INGN and similar high-potential opportunities.
Latest INGN Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, INGN has a neutral consensus with a median price target of $9.00 (ranging from $9.00 to $9.00). The overall analyst rating is Buy (6.7/10). Currently trading at $6.75, the median forecast implies a 33.3% upside. This outlook is supported by 1 Buy, 1 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INGN Analyst Ratings
1
Buy
1
Hold
1
Sell
INGN Price Target Range
Low
$9.00
Average
$9.00
High
$9.00
Current: $6.75
Latest INGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 22, 2025 | Needham | Mike Matson | Buy | Upgrade | $12.00 |
| May 8, 2025 | Stifel | Mathew Blackman | Hold | Maintains | $7.00 |
| Apr 9, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Feb 27, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Feb 26, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Jan 30, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Jan 14, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Nov 8, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Aug 7, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| May 8, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| May 8, 2024 | Stifel | Mathew Blackman | Hold | Maintains | $7.00 |
| Apr 9, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Feb 15, 2024 | William Blair | Margaret Kaczor | Outperform | Upgrade | $0.00 |
| Nov 8, 2023 | JP Morgan | Robbie Marcus | Underweight | Maintains | $7.00 |
| Aug 8, 2023 | Stifel | Mathew Blackman | Hold | Maintains | $8.00 |
| Aug 8, 2023 | JP Morgan | Robbie Marcus | Underweight | Downgrade | $8.00 |
| Jul 14, 2023 | Needham | Mike Matson | Hold | Downgrade | $0.00 |
| Apr 20, 2023 | Needham | Mike Matson | Buy | Reiterates | $26.00 |
| Feb 28, 2023 | Needham | Mike Matson | Buy | Reiterates | $26.00 |
| Feb 24, 2023 | Needham | Mike Matson | Buy | Maintains | $26.00 |
Inogen Inc. (INGN) Competitors
The following stocks are similar to Inogen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Inogen Inc. (INGN) Financial Data
Inogen Inc. has a market capitalization of $177.19M with a P/E ratio of -4.3x. The company generates $339.96M in trailing twelve-month revenue with a -8.1% profit margin.
Revenue growth is +5.5% quarter-over-quarter, while maintaining an operating margin of -9.3% and return on equity of -14.1%.
Valuation Metrics
Market Cap
$177.19M
Enterprise Value
$60.57M
P/E Ratio
-4.3x
PEG Ratio
-4.3x
Price/Sales
0.5x
Growth & Margins
Revenue Growth (YoY)
+5.5%
Gross Margin
+44.2%
Operating Margin
-9.3%
Net Margin
-8.1%
EPS Growth
+5.5%
Financial Health
Cash/Price Ratio
+65.5%
Current Ratio
3.1x
Debt/Equity
9.7x
ROE
-14.1%
ROA
-6.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Inogen Inc. (INGN) Business Model
About Inogen Inc.
What They Do
Develops innovative respiratory products for patients.
Business Model
Inogen generates revenue by designing, manufacturing, and selling portable oxygen concentrators and related respiratory products to patients and healthcare providers. The company operates through a direct-to-consumer model and collaborates with global distributors, enhancing its market presence.
Additional Information
Founded in 2001 and headquartered in Goleta, California, Inogen focuses on research and development to advance respiratory care technology. The company’s portable solutions provide significant mobility and independence for users, marking it as a key player in the healthcare technology sector.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
766
CEO
Mr. Kevin R. M. Smith
Country
United States
IPO Year
2014
Website
www.inogen.comInogen Inc. (INGN) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
What Makes Inogen (INGN) a New Buy Stock
Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
May 16, 2025
By Zacks Equity Research
Tale of the Tape
After Plunging -15.69% in 4 Weeks, Here's Why the Trend Might Reverse for Inogen (INGN)
Inogen (INGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
May 16, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Inogen (INGN) is considered technically oversold, suggesting reduced selling pressure. Analysts are revising earnings estimates upward, indicating a potential trend reversal.
Why It Matters
Inogen's oversold status suggests reduced selling pressure, while upward revisions in earnings estimates signal potential for a price rebound, making it an attractive opportunity for investors.
Source: Zacks Investment Research
Market Sentiment:
Negative
What Makes Inogen (INGN) a New Buy Stock
7 days ago
Quick Summary
Inogen (INGN) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing optimism about its earnings prospects, which may lead to a potential rise in stock value.
Why It Matters
Inogen's upgrade to Zacks Rank #2 signals stronger earnings potential, likely attracting more investors and boosting stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Inogen's Q1 2025 results show growth driven by increased business-to-business sales.
Why It Matters
Inogen's rising business-to-business sales indicate strong demand and potential revenue growth, signaling positive performance and outlook for investors.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Inogen, Inc. (NASDAQ: INGN) will hold its Q1 2025 earnings conference call on May 7, 2025, at 5:00 PM ET, featuring key executives and analysts.
Why It Matters
Inogen's Q1 2025 earnings call will provide insights into its financial performance and strategic direction, influencing investor sentiment and stock price movements.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Inogen reported its financial results for Q1 2025, highlighting developments in their Airway Clearance segment. Further details were shared via Business Wire.
Why It Matters
Inogen's Q1 2025 financial results provide insights into its performance and growth potential, influencing investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Inogen's Q1 2025 revenue and EPS results should be evaluated against Wall Street estimates and year-ago figures for a complete performance assessment.
Why It Matters
Revenue and EPS performance relative to Wall Street estimates and year-ago figures will gauge Inogen's growth, impacting investor confidence and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About INGN Stock
What is Inogen Inc.'s (INGN) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Inogen Inc. (INGN) has a median price target of $9.00. The highest price target is $9.00 and the lowest is $9.00.
Is INGN stock a good investment in 2025?
According to current analyst ratings, INGN has 1 Buy ratings, 1 Hold ratings, and 1 Sell ratings. The stock is currently trading at $6.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INGN stock?
Wall Street analysts predict INGN stock could reach $9.00 in the next 12 months. This represents a 33.3% increase from the current price of $6.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Inogen Inc.'s business model?
Inogen generates revenue by designing, manufacturing, and selling portable oxygen concentrators and related respiratory products to patients and healthcare providers. The company operates through a direct-to-consumer model and collaborates with global distributors, enhancing its market presence.
What is the highest forecasted price for INGN Inogen Inc.?
The highest price target for INGN is $9.00 from at , which represents a 33.3% increase from the current price of $6.75.
What is the lowest forecasted price for INGN Inogen Inc.?
The lowest price target for INGN is $9.00 from at , which represents a 33.3% increase from the current price of $6.75.
What is the overall INGN consensus from analysts for Inogen Inc.?
The overall analyst consensus for INGN is neutral. Out of 6 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 1 as Sell, with a median price target of $9.00.
How accurate are INGN stock price projections?
Stock price projections, including those for Inogen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 5:21 PM UTC